BR112023018980A2 - Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada - Google Patents

Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada

Info

Publication number
BR112023018980A2
BR112023018980A2 BR112023018980A BR112023018980A BR112023018980A2 BR 112023018980 A2 BR112023018980 A2 BR 112023018980A2 BR 112023018980 A BR112023018980 A BR 112023018980A BR 112023018980 A BR112023018980 A BR 112023018980A BR 112023018980 A2 BR112023018980 A2 BR 112023018980A2
Authority
BR
Brazil
Prior art keywords
growth hormone
long
methods
administration
acting
Prior art date
Application number
BR112023018980A
Other languages
English (en)
Inventor
Aleksandra Pastrak
Francisco Cara Jóse
Paul Wajnrajch Michael
Rao Valluri Srinivas
Original Assignee
Opko Biologics Ltd
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd, Pfizer filed Critical Opko Biologics Ltd
Publication of BR112023018980A2 publication Critical patent/BR112023018980A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada. a presente invenção refere-se a métodos de tratamento de distúrbios relacionados a hormônio de crescimento administrando um hormônio de crescimento humano recombinante de ação prolongada. em outra concretização, um hormônio de crescimento humano recombinante de ação prolongada é administrado em uma composição ou a combina-ção é administrada separadamente para tratar a deficiência de crescimento em um indivíduo previamente tratado com uma terapia de rhgh uma vez ao dia.
BR112023018980A 2021-03-19 2022-03-17 Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada BR112023018980A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163504P 2021-03-19 2021-03-19
US202163272417P 2021-10-27 2021-10-27
PCT/US2022/020804 WO2022197961A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Publications (1)

Publication Number Publication Date
BR112023018980A2 true BR112023018980A2 (pt) 2023-12-05

Family

ID=83320806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018980A BR112023018980A2 (pt) 2021-03-19 2022-03-17 Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada

Country Status (10)

Country Link
US (1) US20240166710A1 (pt)
EP (1) EP4308151A1 (pt)
JP (1) JP2022145646A (pt)
KR (1) KR20230171936A (pt)
AU (1) AU2022238386A1 (pt)
BR (1) BR112023018980A2 (pt)
CA (1) CA3214273A1 (pt)
IL (1) IL305661A (pt)
MX (1) MX2023010997A (pt)
WO (1) WO2022197961A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
US8329750B2 (en) * 2008-02-11 2012-12-11 Depomed, Inc. Methods for treating vasomotor symptoms using GABA analogs in a gastric retentive dosage form
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PT3220892T (pt) * 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
CN107438623B (zh) * 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法

Also Published As

Publication number Publication date
US20240166710A1 (en) 2024-05-23
WO2022197961A1 (en) 2022-09-22
EP4308151A1 (en) 2024-01-24
JP2022145646A (ja) 2022-10-04
IL305661A (en) 2023-11-01
MX2023010997A (es) 2023-11-28
CA3214273A1 (en) 2022-09-22
AU2022238386A1 (en) 2023-09-14
KR20230171936A (ko) 2023-12-21

Similar Documents

Publication Publication Date Title
Zhou et al. Efficiency of neuromuscular electrical stimulation and transcutaneous nerve stimulation on hemiplegic shoulder pain: a randomized controlled trial
Zhang et al. Electroacupuncture attenuates inflammation in a rat model
Shankar et al. Autonomic status and pain profile in patients of chronic low back pain and following electro acupuncture therapy: a randomized control trial
Kumnerddee et al. Efficacy of electro-acupuncture in chronic plantar fasciitis: a randomized controlled trial
Picelli et al. Efficacy of therapeutic ultrasound and transcutaneous electrical nerve stimulation compared with botulinum toxin type A in the treatment of spastic equinus in adults with chronic stroke: a pilot randomized controlled trial
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
BR112015022257A2 (pt) uso de uma proteína de fusão de hormônio de crescimento humano-xten (hgh-xten), dose em bolus pediátrica de uma proteína de fusão hgh-xten e kit
Koutná Carboxytherapy in aesthetic medicine
de Almeida et al. A hypothesis for the anti-inflammatory and mechanotransduction molecular mechanisms underlying acupuncture tendon healing
WO2022076556A3 (en) Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
CL2021002049A1 (es) Administración de virus adenoasociado de polinucleótido de cln3.
BR112023018980A2 (pt) Métodos de administração de polipeptídeos de hormônio de crescimento de ação prolongada
Liu et al. Physiologic effects of electroacupuncture combined with intramuscular administration of xylazine to provide analgesia in goats
BR112018016817A2 (pt) composição farmacêutica e método de tratamento da deficiência do hormônio do crescimento
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
Odell Jr et al. New technique combines electrical currents and local anesthetic for pain management
Kanvee et al. Comparative study of clonidine and dexmedetomidine as an adjuvant with ropivacaine in supraclavicular brachial plexus block for upper limb surgery
Anwar et al. Combined botulinum toxin injections and phenol nerve/motor point blocks to manage multifocal spasticity in adults
Naik et al. Comparative study of acupressure wristband versus palonosetron for prophylaxis of postoperative nausea and vomiting in elective laparoscopic cholecystectomy under general anaesthesia
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa
CA3069256A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
US20160136417A1 (en) Treating skin ulcers
Feng et al. Periarthritis of shoulder treated with Fu's subcutaneous needling and electroacupuncture: A control trail
Ay et al. Comparison of kinesio taping, trigger point injection, and neural therapy in the treatment of acute myofascial pain syndrome: A randomized controlled study